209 related articles for article (PubMed ID: 30811933)
21. Long-Acting HIV-1 Fusion Inhibitory Peptides and their Mechanisms of Action.
Wang C; Cheng S; Zhang Y; Ding Y; Chong H; Xing H; Jiang S; Li X; Ma L
Viruses; 2019 Sep; 11(9):. PubMed ID: 31480738
[TBL] [Abstract][Full Text] [Related]
22. The M-T hook structure increases the potency of HIV-1 fusion inhibitor sifuvirtide and overcomes drug resistance.
Chong H; Yao X; Qiu Z; Sun J; Qiao Y; Zhang M; Wang M; Cui S; He Y
J Antimicrob Chemother; 2014 Oct; 69(10):2759-69. PubMed ID: 24908047
[TBL] [Abstract][Full Text] [Related]
23. gp41 sequence variability in HIV type 1 non-B subtypes infected patients undergoing enfuvirtide pressure.
D'Arrigo R; Ciccozzi M; Gori C; Montieri S; Aquaro S; Bellagamba R; Boumis E; Di Perri G; Pizzi D; Antinori A; Rezza G; Perno CF
AIDS Res Hum Retroviruses; 2007 Oct; 23(10):1296-302. PubMed ID: 17961119
[TBL] [Abstract][Full Text] [Related]
24. Approaches for identification of HIV-1 entry inhibitors targeting gp41 pocket.
Yu F; Lu L; Du L; Zhu X; Debnath AK; Jiang S
Viruses; 2013 Jan; 5(1):127-49. PubMed ID: 23344560
[TBL] [Abstract][Full Text] [Related]
25. Heptad-repeat-2 mutations enhance the stability of the enfuvirtide-resistant HIV-1 gp41 hairpin structure.
Jenwitheesuk E; Samudrala R
Antivir Ther; 2005; 10(8):893-900. PubMed ID: 16430194
[TBL] [Abstract][Full Text] [Related]
26. Artificial peptides conjugated with cholesterol and pocket-specific small molecules potently inhibit infection by laboratory-adapted and primary HIV-1 isolates and enfuvirtide-resistant HIV-1 strains.
Wang C; Shi W; Cai L; Lu L; Yu F; Wang Q; Jiang X; Xu X; Wang K; Xu L; Jiang S; Liu K
J Antimicrob Chemother; 2014 Jun; 69(6):1537-45. PubMed ID: 24500189
[TBL] [Abstract][Full Text] [Related]
27. Short-peptide fusion inhibitors with high potency against wild-type and enfuvirtide-resistant HIV-1.
Chong H; Yao X; Qiu Z; Sun J; Zhang M; Waltersperger S; Wang M; Liu SL; Cui S; He Y
FASEB J; 2013 Mar; 27(3):1203-13. PubMed ID: 23233535
[TBL] [Abstract][Full Text] [Related]
28. Improved Pharmacological and Structural Properties of HIV Fusion Inhibitor AP3 over Enfuvirtide: Highlighting Advantages of Artificial Peptide Strategy.
Zhu X; Zhu Y; Ye S; Wang Q; Xu W; Su S; Sun Z; Yu F; Liu Q; Wang C; Zhang T; Zhang Z; Zhang X; Xu J; Du L; Liu K; Lu L; Zhang R; Jiang S
Sci Rep; 2015 Aug; 5():13028. PubMed ID: 26286358
[TBL] [Abstract][Full Text] [Related]
29. A novel chimeric protein-based HIV-1 fusion inhibitor targeting gp41 glycoprotein with high potency and stability.
Pan C; Cai L; Lu H; Lu L; Jiang S
J Biol Chem; 2011 Aug; 286(32):28425-34. PubMed ID: 21690094
[TBL] [Abstract][Full Text] [Related]
30. Inhibitors of viral entry.
Melby T; Westby M
Handb Exp Pharmacol; 2009; (189):177-202. PubMed ID: 19048201
[TBL] [Abstract][Full Text] [Related]
31. Revisiting the mechanism of enfuvirtide and designing an analog with improved fusion inhibitory activity by targeting triple sites in gp41.
Xu W; Pu J; Su S; Hua C; Su X; Wang Q; Jiang S; Lu L
AIDS; 2019 Aug; 33(10):1545-1555. PubMed ID: 30932963
[TBL] [Abstract][Full Text] [Related]
32. HIV-1 gp41 heptad repeat 2 (HR2) possesses an amino acid domain that resembles the allergen domain in Aspergillus fumigatus Asp f1 protein: review, hypothesis and implications.
Becker Y
Virus Genes; 2007 Jun; 34(3):233-40. PubMed ID: 17333401
[TBL] [Abstract][Full Text] [Related]
33. Impact of human immunodeficiency virus type 1 gp41 amino acid substitutions selected during enfuvirtide treatment on gp41 binding and antiviral potency of enfuvirtide in vitro.
Mink M; Mosier SM; Janumpalli S; Davison D; Jin L; Melby T; Sista P; Erickson J; Lambert D; Stanfield-Oakley SA; Salgo M; Cammack N; Matthews T; Greenberg ML
J Virol; 2005 Oct; 79(19):12447-54. PubMed ID: 16160172
[TBL] [Abstract][Full Text] [Related]
34. Mechanism of HIV-1 Resistance to Short-Peptide Fusion Inhibitors Targeting the Gp41 Pocket.
Su Y; Chong H; Qiu Z; Xiong S; He Y
J Virol; 2015 Jun; 89(11):5801-11. PubMed ID: 25787278
[TBL] [Abstract][Full Text] [Related]
35. Electrostatically constrained alpha-helical peptide inhibits replication of HIV-1 resistant to enfuvirtide.
Nishikawa H; Nakamura S; Kodama E; Ito S; Kajiwara K; Izumi K; Sakagami Y; Oishi S; Ohkubo T; Kobayashi Y; Otaka A; Fujii N; Matsuoka M
Int J Biochem Cell Biol; 2009 Apr; 41(4):891-9. PubMed ID: 18834950
[TBL] [Abstract][Full Text] [Related]
36. Design of an engineered N-terminal HIV-1 gp41 trimer with enhanced stability and potency.
Dwyer JJ; Wilson KL; Martin K; Seedorff JE; Hasan A; Medinas RJ; Davison DK; Feese MD; Richter HT; Kim H; Matthews TJ; Delmedico MK
Protein Sci; 2008 Apr; 17(4):633-43. PubMed ID: 18359857
[TBL] [Abstract][Full Text] [Related]
37. Development of Protein- and Peptide-Based HIV Entry Inhibitors Targeting gp120 or gp41.
Pu J; Wang Q; Xu W; Lu L; Jiang S
Viruses; 2019 Aug; 11(8):. PubMed ID: 31374953
[TBL] [Abstract][Full Text] [Related]
38. Development of Small-molecule HIV Entry Inhibitors Specifically Targeting gp120 or gp41.
Lu L; Yu F; Cai L; Debnath AK; Jiang S
Curr Top Med Chem; 2016; 16(10):1074-90. PubMed ID: 26324044
[TBL] [Abstract][Full Text] [Related]
39. Mutations of Gln64 in the HIV-1 gp41 N-terminal heptad repeat render viruses resistant to peptide HIV fusion inhibitors targeting the gp41 pocket.
Yu X; Lu L; Cai L; Tong P; Tan S; Zou P; Meng F; Chen YH; Jiang S
J Virol; 2012 Jan; 86(1):589-93. PubMed ID: 22013063
[TBL] [Abstract][Full Text] [Related]
40. Resistance and replicative capacity of HIV-1 strains selected in vivo by long-term enfuvirtide treatment.
Menzo S; Castagna A; Monachetti A; Hasson H; Danise A; Carini E; Bagnarelli P; Lazzarin A; Clementi M
New Microbiol; 2004 Apr; 27(2 Suppl 1):51-61. PubMed ID: 15646065
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]